CAL
BOLT icon

Capital Advisors Ltd’s Bolt Biotherapeutics BOLT Stock Holding History

Capital Advisors Ltd’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5
Closed – – 1252
2022
Q2 		$0 Buy
+5
New +$194 ﹤0.01% 1020

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Capital Advisors Ltd's BOLT Position: Q3 2022 in Review

Capital Advisors Ltd sold out of Bolt Biotherapeutics (BOLT) in Q3 2022, closing a stake of 5 shares.

Capital Advisors Ltd first reported a position in BOLT in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 56 funds tracked by Wall St. Rank hold BOLT as of Q3 2022.

  • Capital Advisors Ltd reported no remaining Bolt Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 5 Bolt Biotherapeutics shares in Q3 2022.
  • Capital Advisors Ltd first reported a position in Bolt Biotherapeutics in Q2 2022 and held it in 1 quarter.
  • Capital Advisors Ltd's Bolt Biotherapeutics position peaked at $0 in Q2 2022.
  • 56 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2022.

Based on Capital Advisors Ltd's 13F filing for Q3 2022, filed 9 Nov 2022.